Dr. Hampel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st Street SW
Rochester, MN 55905
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2018 - 2021- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2015 - 2018
University of Missouri-Columbia School of MedicineClass of 2015
Certifications & Licensure
MN State Medical License 2016 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 21 citationsChronic lymphocytic leukemia treatment algorithm 2022.Paul J Hampel, Sameer A Parikh
Blood Cancer Journal. 2022-11-29 - 16 citationsIncidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice.Amber B. Koehler, Nelson Leung, Timothy G. Call, Kari G. Rabe, Sara J. Achenbach
Leukemia & Lymphoma. 2020-05-25 - 42 citationsRapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practicePaul J. Hampel, Wei Ding, Timothy G. Call, Kari G. Rabe, Saad S. Kenderian
Leukemia & Lymphoma. 2019-04-24
Journal Articles
- Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib in Routine Clinical Practice at an Academic Medical CentreSameer A Parikh, Tait D Shanafelt, Paul J Hampel, Jose F Leis, Neil E Kay, Wei Ding, Timothy G Call, Deborah Bowen, Eli Muchtar, British Journal of Haematology
Lectures
- BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Rapid progression of disease following ibrutinib discontinuation in patients with chronic lymphocytic leukemia.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
